bioRxiv Science⌕ Search

Biology subjects

Caramazza, P.

Publications and source records attributed to Caramazza, P..

2 recordsLinked to original sources

Millisecond nonlinear state changes during droplet coalescence identify therapeutic-antibody developability liabilities

Apoha's Liquid State Machine records ellipsometric waveforms from injections depositing sub-microgram quantities of antibody drop-by-drop onto a liquid reservoir. We previously showed that a behavioural feature extracted from the waveforms, VIBE1, identified antibodies carrying multiple biophysical liabilities in an industrial dataset of 71 monoclonal antibodies, and enriched for clinical failure across a larger dataset of 235 therapeutic antibodies. Here, we use an auxiliary coalescence-sensor channel to decode VIBE1 by separating the coalescence event from its propagation through the substrate. The per-titration drop-to-drop standard deviation of pinch-off time, {sigma}{tau}, explains most of VIBE1's variance across the dataset (R2 = 0.92, n = 1182). High-speed imaging at 10,000 frames per second reveals that all imaged drops initially thin at the same Newtonian capillary-inertial rate while the neck remains wide. In drops from certain antibodies, the thinning bridge then decelerates as internal strain builds in the narrowing neck. This elastocapillary stiffening response has a timescale {lambda} that decreases as pinch-off time {tau}i increases across the imaged set. {sigma}{tau} is therefore a readout of the antibody's propensity to undergo a transient gel-like stiffening response during coalescence, and that variability is what VIBE1 captures. The signal is concentration dependent, and absent in bovine serum albumin (BSA) tested at up to an order of magnitude higher concentration than the antibodies, despite BSA being a strongly surface-active globular protein. The instrument is configured so that complex behaviours of this kind appear in its recorded waveforms; the gel-like coalescence response we identify here is one such phenomenon.

biophysics↗

A High-Dimensional Interfacial Wave Assay for Early Biophysical Profiling of Therapeutic Antibodies

Therapeutic antibody performance depends not only on sequence and structure, but also on how the molecule responds to physico-chemical perturbations encountered in its environment. Whereas sequence and static structure can be inferred under controlled conditions, behaviour is a conditional, multidimensional response to environment, most directly characterised by applying defined perturbations and quantifying the resulting dynamics. Conventional early-stage developability methods capture isolated dimensions of this response under near-equilibrium conditions, deferring integrated behavioural assessment to late-stage characterisation, when the cost of correction is highest. We introduce Variations in Interfacial Behaviour under Excitation (VIBE), an interfacial wave method implemented via Liquid State Intelligence (LSI), a sensing architecture that transduces molecular perturbations at the air-liquid interface into high-dimensional wave patterns. A colloidal liquid substrate operated near a thermodynamic transition couples small molecular perturbations to large dynamical responses, integrating structural flexibility, charge distribution, and surface hydrophobicity into a single behavioural readout from microgram-scale samples. Applied to antibodies previously characterised by industrial benchmarks, the primary behavioural descriptor, VIBE1, functioned as a high-precision triage tool, flagging candidates carrying multiple biophysical liabilities. In a clinical-stage cohort, the proportion of high-VIBE1 antibodies declined progressively from early trials through approval, and high-VIBE1 candidates showed an elevated clinical failure rate. Concordance analysis against estab-lished methods confirmed that VIBE1 captures a composite signal spanning hydrophobicity, polyreactivity, self-interaction, and thermal stability rather than recapitulating any single conventional readout. These findings establish interfacial wave sensing as a low-material modality for early-stage developability assessment, repositioning molecular behaviour from late-stage validation to discovery-phase characterisation.

biophysics↗